Latest NewsRare Disease Patient CEO Joins “Orphan Drug Development Guidebook” Task Force
Patient-driven gene therapy company ReflectionBio receives Orphan Drug Designation
from U.S. FDA for the treatment of Bietti's Crystalline Dystrophy (BCD)
Our FocusReflection Biotechnologies (ReflectionBio) focuses on rare, genetic diseases and other challenging diseases which currently have no or few treatment options available. Rare disease patients shoulder the inevitable odds of genetic mutations for mankind, but are often ignored by society and under-supported by public resources. At ReflectionBio, we aim to develop life-changing, long-lasting and breakthrough gene therapies for patients suffering from these devastating diseases.
Our Patient OriginReflectionBio was founded and is driven by a patient and family suffering from a rare disease. The founders of ReflectionBio collectively have more than 25 years of experience in science, law, finance, and technology collaboration and management.
Our “By Patients, For Patients” ApproachWith a unique patient origin and background, ReflectionBio created and applies a "By Patients, For Patients" approach to accelerate research and development process for the treatment of rare diseases, bring more hope to the patient community, and promote awareness of overlooked diseases in the pharmaceutical industry. Through this "By Patients, For Patients" approach, patients and families combine efforts and play a more active role in initiating, coordinating, incubating and/or even driving R&D projects to develop treatments for rare diseases and other challenging diseases.
Our BeliefWith faith, relentless efforts and the right partners, We, the Patients, can make a difference in driving R&D to help ourselves and others.
Our TechnologyReflectionBio focuses on developing gene therapy and other novel treatments for diseases that are considered “incurable” today, including rare diseases and other challenging diseases. Gene therapy is a revolutionary technology that can be used to treat many diseases at the root level.
(More on Gene Therapy)